Skip to main content
Clinical Trials/NCT06081647
NCT06081647RecruitingNot Applicable

The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway Reduce the Incidence of Hypoxia in Patients Undergoing Gastrointestinal Endoscopy Sedated With Propofol.

RenJi Hospital10 sites in 1 country1,200 target enrollmentStarted: December 27, 2023Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
1,200
Locations
10
Primary Endpoint
The incidence of hypoxia

Study Overview

Brief Summary

Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing gastrointestinal endoscopy with propofol. A recent innovation in this domain is the COMBO Endoscopy Oropharyngeal Airway-a multifaceted device that encompasses capnography monitoring, bite block , oxygenation support, and oropharyngeal airway management. This device has been purposefully designed to cater to the unique requirements of endoscopic procedures. The principal objective of our randomized study is to assess the efficacy and safety of the COMBO Endoscopy Oropharyngeal Airway reduce the incidence of hypoxia on patients undergoing gastrointestinal endoscopy under propofol sedation.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Age 18≤ Age ≤
  • •Patients undergoing gastroendoscopy and/or colonoscopy procedure.
  • •Patients have signed the informed consent form.
  • •The ASA classification ranges from I to II.
  • •The estimated duration of the procedure does not exceed 45 minutes.

Exclusion Criteria

  • •Patients who exhibit contraindications to oropharyngeal airway ventilation, such as coagulation disorders, a predisposition to oral and nasal bleeding, mucosal damage, or anatomical constraints impeding oropharyngeal channel placement.
  • •Severe cardiac insufficiency, defined as a maximal exercise capacity of less than 4 metabolic equivalents (METs).
  • •Profound renal insufficiency necessitating preoperative dialysis.
  • •A confirmed severe liver dysfunction.
  • •Patients diagnosed with chronic obstructive pulmonary disease (COPD) or those presently experiencing other acute and chronic pulmonary conditions necessitating prolonged or intermittent oxygen therapy.
  • •Elevated intracranial pressure.
  • •Upper respiratory tract infections, encompassing the oral, nasal, and pharyngeal regions.
  • •Fever, defined as a core body temperature exceeding 37.5 degrees Celsius.
  • •Pregnancy or lactation.
  • •Hypersensitivity reactions to sedatives like propofol or medical equipment such as adhesive tape.
  • •Urgent surgical intervention.
  • •Polytrauma.
  • •Peripheral oxygen saturation (SpO2) levels below 95% while breathing room air preoperatively.
  • •BMI<18.5 or BMI>
  • •Patients with a documented history of substance abuse, specifically drugs and/or alcohol, within the two years preceding the commencement of the screening period. Substance abuse in this context is defined as consuming more than three standard alcoholic beverages daily, roughly equivalent to 10g of alcohol or 50g of Chinese Baijiu.
  • •Patients with a history of mental and neurological disorders, including but not limited to depression, severe central nervous system depression, Parkinson's disease, basal ganglia lesions, schizophrenia, epilepsy, Alzheimer's disease, and myasthenia gravis.
  • •Presently engaged in concurrent participation in additional clinical trials.
  • •Patients considered ineligible by researchers for inclusion in this clinical trial.

Arms & Interventions

the COMBO Endoscopy Oropharyngeal Airway Group

Experimental

In this group, patients use the COMBO Endoscopy Oropharyngeal Airway for oxygenation.

Intervention: the COMBO Endoscopy Oropharyngeal Airway (Device)

Regular Nasal Cannula Group

Active Comparator

In this group, patients use the regular nasal cannula for oxygenation.

Intervention: Regular Nasal Cannula (Device)

Outcomes

Primary Outcomes

The incidence of hypoxia

Time Frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours

(75% ≤ SpO2 \< 90% for \<60 s)

Secondary Outcomes

  • The incidence of severe hypoxia(Patients will be followed for the duration of hospital stay, an expected average about 2 hours)
  • The incidence of sub-clinical respiratory depression(Patients will be followed for the duration of hospital stay, an expected average about 2 hours)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

diansan su

Vice Chair of the Department of Anesthesiology

RenJi Hospital

Study Sites (10)

Loading locations...

Similar Trials